Adefovir dipivoxil in (lamivudine-resistant) hepatitis B patients – Study 461

Ongoing 48-week, randomized, double-blind,

placebo-controlled, multicenter study of 59 patients

with chronic hepatitis B due to lamivudine-resistant

HBV.

Patients were randomized to receive either adefovir dipivoxil 10 mg (n = 20), or adefovir dipivoxil 10 mg plus lamivudine 100 mg (n = 20), or lamivudine 100 mg (n = 19).

Previous slide

Next slide

Back to first slide

View graphic version